Patents by Inventor Dong-Mei Feng

Dong-Mei Feng has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20070244055
    Abstract: Chemical conjugates which comprise oligopeptides, having amino acid sequences that are selectively proteolytically cleaved by free prostate specific antigen (PSA) and known cytotoxic agents are disclosed. The conjugates of the invention are characterized by attachment of the cleavable oligopeptide to the oxygen atom at the 4-position on a vinca drug that has be desacetylated. Such conjugates are useful in the treatment of prostatic cancer and benign prostatic hypertrophy (BPH).
    Type: Application
    Filed: June 6, 2007
    Publication date: October 18, 2007
    Inventors: Stephen Brady, Dong-Mei Feng, Victor Garsky
  • Publication number: 20070189865
    Abstract: Compounds disclosed herein are bradykinin B1 antagonists or inverse agonists useful in the treatment or prevention of symptoms such as pain and inflammation associated with the bradykinin B1 pathway.
    Type: Application
    Filed: February 25, 2005
    Publication date: August 16, 2007
    Inventors: Mark Bock, Dong-Mei Feng, Scott Kuduk
  • Publication number: 20070129309
    Abstract: Chemical conjugates which comprise oligopeptides, having amino acid sequences that are selectively proteolytically cleaved by free prostate specific antigen (PSA) and known cytotoxic agents are disclosed. The conjugates of the invention are characterized by attachment of the cleavable oligopeptide to the oxygen atom at the 4-position on a vinca drug that has be deacetylated. Such conjugates are useful in the treatment of prostatic cancer and benign prostatic hypertrophy (BPH).
    Type: Application
    Filed: January 18, 2007
    Publication date: June 7, 2007
    Inventors: Stephen Brady, Dong-Mei Feng, Victor Garsky
  • Publication number: 20070021350
    Abstract: Chemical conjugates which comprise oligopeptides, having amino acid sequences that are selectively proteolytically cleaved by free prostate specific antigen (PSA) and known cytotoxic agents are disclosed. The conjugates of the invention are characterized by attachment of the cleavable oligopeptide to the oxygen atom at the 4-position on a vinca drug that has be desacetylated. Such conjugates are useful in the treatment of prostatic cancer and benign prostatic hypertrophy (BPH).
    Type: Application
    Filed: September 26, 2006
    Publication date: January 25, 2007
    Inventors: Stephen Brady, Dong-Mei Feng, Victor Garsky
  • Patent number: 7091380
    Abstract: N-Biphenyl(substituted methyl) aminocycloalkanecarboxamide derivatives are bradykinin B1 antagonists or inverse agonists useful in the treatment or prevention of symptoms such as pain and inflammation associated with the bradykinin B1 pathway.
    Type: Grant
    Filed: February 4, 2003
    Date of Patent: August 15, 2006
    Assignee: Merck & Co., Inc.
    Inventors: Michael R. Wood, Neville J. Anthony, Mark G. Bock, Dong-Mei Feng, Scott D. Kuduk, Dai-Shi Su, Jenny Miu-chun Wai
  • Publication number: 20060148718
    Abstract: Chemical conjugates which comprise oligopeptides, having amino acid sequences that are selectively proteolytically cleaved by free prostate specific antigen (PSA) and known cytotoxic agents are disclosed. The conjugates of the invention are characterized by attachment of the cleavable oligopeptide to the oxygen atom at the 4-position on a vinca drug that has be desacetylated. Such conjugates are useful in the treatment of prostatic cancer and benign prostatic hypertrophy (BPH).
    Type: Application
    Filed: February 24, 2006
    Publication date: July 6, 2006
    Inventors: Stephen Brady, Dong-Mei Feng, Victor Garsky
  • Patent number: 6919343
    Abstract: N-Biphenyl(substituted methyl)aminocycloalkanecarboxamide derivatives are bradykinin B1 antagonists or inverse agonists useful in the treatment or prevention of symptoms such as pain and inflammation associated with the bradykinin B1 pathway.
    Type: Grant
    Filed: January 30, 2003
    Date of Patent: July 19, 2005
    Assignee: Merck & Co., Inc.
    Inventors: Michael R. Wood, Neville J. Anthony, Mark G. Bock, Dong-Mei Feng, Scott D. Kuduk, Dai-Shi Su, Jenny Miu-chun Wai
  • Publication number: 20050119166
    Abstract: Chemical conjugates which comprise oligopeptides, having amino acid sequences that are selectively proteolytically cleaved by free prostate specific antigen (PSA) and known cytotoxic agents are disclosed. The conjugates of the invention are characterized by attachment of the cleavable oligopeptide to the oxygen atom at the 4-position on a vinca drug that has be desacetylated. Such conjugates are useful in the treatment of prostatic cancer and benign prostatic hypertrophy (BPH).
    Type: Application
    Filed: December 6, 2004
    Publication date: June 2, 2005
    Inventors: Stephen Brady, Dong-Mei Feng, Victor Garsky
  • Publication number: 20050085667
    Abstract: N-Biphenyl(substituted methyl) aminocycloalkanecarboxamide derivatives are bradykinin B1 antagonists or inverse agonists useful in the treatment or prevention of symptoms such as pain and inflammation associated with the bradykinin B1 pathway.
    Type: Application
    Filed: February 4, 2003
    Publication date: April 21, 2005
    Inventors: Michael Wood, Neville Anthony, Mark Bock, Dong-Mei Feng, Scott Kuduk, Dai-Shi Su, Jenny Wai
  • Publication number: 20050084463
    Abstract: N-Biphenyl(substituted methyl)aminocycloalkanecarboxamide derivatives are bradykinin B1 antagonists or inverse agonists useful in the treatment or prevention of symptoms such as pain and inflammation associated with the bradykinin B1 pathway.
    Type: Application
    Filed: February 4, 2003
    Publication date: April 21, 2005
    Inventors: Michael Wood, Neville Anthony, Marg Bock, Dong-Mei Feng, Scott Kuduk, Dai-Shi Su, Jenny Wau
  • Publication number: 20040081659
    Abstract: Chemical conjugates which comprise oligopeptides, having amino acid sequences that are selectively proteolytically cleaved by free prostate specific antigen (PSA) and known cytotoxic agents are disclosed. The conjugates of the invention are characterized by attachment of the cleavable oligopeptide to the oxygen atom at the 4-position on a vinca drug that has be desacetylated. Such conjugates are useful in the treatment of prostatic cancer and benign prostatic hypertrophy (BPH).
    Type: Application
    Filed: August 15, 2003
    Publication date: April 29, 2004
    Applicant: Merck & Co., Inc.
    Inventors: Stephen F. Brady, Dong-Mei Feng, Victor M. Garsky
  • Publication number: 20040063761
    Abstract: Compounds disclosed herein are bradykinin B1 antagonist compounds useful in the treatment or prevention of symptoms such as pain and inflammation associated with the bradykinin B1 pathway.
    Type: Application
    Filed: August 5, 2003
    Publication date: April 1, 2004
    Inventors: Scott D. Kuduk, Mark G. Bock, Dong-Mei Feng, Jenny Miu-Chun Wai
  • Publication number: 20040044041
    Abstract: Compounds disclosed herein are bradykinin B1 antagonist compounds useful in the treatment or prevention of symptoms such as pain and inflammation associated with the bradykinin B1 pathway.
    Type: Application
    Filed: August 5, 2003
    Publication date: March 4, 2004
    Inventors: Scott D. Kuduk, Mark G. Bock, Dong-Mei Feng, Dai-Shi Su, Jenny Miu-Chun Wai
  • Publication number: 20040034064
    Abstract: Compounds disclosed herein are bradykinin B1 antagonist compounds useful in the treatment or prevention of symptoms such as pain and inflammation associated with the bradykinin B1 pathway.
    Type: Application
    Filed: August 5, 2003
    Publication date: February 19, 2004
    Inventors: Scott D. Kuduk, Mark G. Bock, Dong-Mei Feng, Jenny Miu-Chun Wai
  • Publication number: 20040029920
    Abstract: Compounds disclosed herein are bradykinin B1 antagonist compounds useful in the treatment or prevention of symptoms such as pain and inflammation associated with the bradykinin B1 pathway.
    Type: Application
    Filed: August 5, 2003
    Publication date: February 12, 2004
    Inventors: Scott D. Kuduk, Mark G. Bock, Dong-Mei Feng, Jenny Miu-Chun Wai
  • Publication number: 20030232760
    Abstract: Chemical conjugates which comprise oligopeptides, having amino acid sequences that are selectively proteolytically cleaved by free prostate specific antigen (PSA) and known cytotoxic agents are disclosed. Such conjugates are useful in the treatment of prostatic cancer and benign prostatic hypertrophy (BPH).
    Type: Application
    Filed: June 6, 2003
    Publication date: December 18, 2003
    Applicant: Merck & Co., Inc.
    Inventors: Victor M. Garsky, Dong-Mei Feng, Defeo-Jones Deborah
  • Publication number: 20030220375
    Abstract: N-Biphenyl(substituted methyl)aminocycloalkanecarboxamide derivatives are bradykinin B1 antagonists or inverse agonists useful in the treatment or prevention of symptoms such as pain and inflammation associated with the bradykinin B1 pathway.
    Type: Application
    Filed: January 30, 2003
    Publication date: November 27, 2003
    Inventors: Michael R. Wood, Neville J. Anthony, Mark G. Bock, Dong-Mei Feng, Scott D. Kuduk, Dai-Shi Su, Jenny Miu-chun Wai
  • Publication number: 20020115596
    Abstract: Chemical conjugates which comprise oligopeptides, having amino acid sequences that are selectively proteolytically cleaved by free prostate specific antigen (PSA) and known cytotoxic agents are disclosed. Such conjugates are useful in the treatment of prostatic cancer and benign prostatic hypertrophy (BPH).
    Type: Application
    Filed: September 21, 2001
    Publication date: August 22, 2002
    Applicant: Merk & Co., Inc.
    Inventors: Victor M. Garsky, Dong-Mei Feng, Defeo-Jones Deborah
  • Publication number: 20020103136
    Abstract: Chemical conjugates which comprise oligopeptides, having amino acid sequences that are selectively proteolytically cleaved by free prostate specific antigen (PSA) and known cytotoxic agents are disclosed. The conjugates of the invention are characterized by a hydroxylalkylamino linker between the oligopeptide and vinblastine. Such conjugates are useful in the treatment of prostatic cancer and benign prostatic hypertrophy (BPH). Also disclosed are novel cytotoxic agents that are derivatives of vinca alkaloid drugs.
    Type: Application
    Filed: August 8, 2001
    Publication date: August 1, 2002
    Inventor: Dong-Mei Feng
  • Patent number: 6391305
    Abstract: Chemical conjugates which comprise oligopeptides, having amino acid sequences that are selectively proteolytically cleaved by free prostate specific antigen (PSA), hydrophilic oligopeptide blocking groups and known cytotoxic agents are disclosed. Such conjugates are useful in the treatment of prostatic cancer and benign prostatic hypertrophy (BPH).
    Type: Grant
    Filed: June 28, 1999
    Date of Patent: May 21, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Dong-Mei Feng, Victor M. Garsky, Raymond E. Jones, Allen I. Oliff, Jenny M. Wai